Discover investment opportunities in Small Cap Defense Stocks Q3 2025 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Small Cap Defense Stocks Q3 2025 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Small Cap Defense Stocks Q3 2025 using our Smart AI Filter.
8 stocks found for "Small Cap Defense Stocks Q3 2025"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.83 Risk measure | ±47.0% Price volatility | 28.3 Valuation | 0.32% Annual yield | |||
1.56 Risk measure | ±52.2% Price volatility | 46.5 Valuation | 0.00% Annual yield | |||
0.48 Risk measure | ±92.0% Price volatility | -0.2 Valuation | 0.00% Annual yield | |||
0.88 Risk measure | ±44.2% Price volatility | 75.7 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±57.6% Price volatility | 128.3 Valuation | 0.00% Annual yield | |||
1.38 Risk measure | ±49.7% Price volatility | 57.0 Valuation | 0.00% Annual yield | |||
0.43 Risk measure | ±43.9% Price volatility | 7.1 Valuation | 6.05% Annual yield | |||
0.53 Risk measure | ±61.7% Price volatility | 248.5 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What defense sector strengths do AVAV and KRNT offer?
A: AVAV and KRNT provide growth potential through innovations in unmanned systems and advanced manufacturing technologies. AVAV specializes in drones used for defense, while KRNT leverages advanced inkjet technology in its manufacturing processes, which can meet military specifications.
Q: How does MRCY's focus on technology enhance its appeal to investors?
A: MRCY excels in defense electronics, integrating cutting-edge tech into military operations, which can be attractive to investors seeking exposure to high-tech defense solutions. Their specialization in secure, innovative electronics positions them to benefit from increased defense spending.
Q: What potential income opportunities do investors find in AXON?
A: AXON, known for its law enforcement technology solutions, does not have a strong dividend focus but may offer capital appreciation from growing technology adoption in public safety. Investors might consider this for growth rather than income.
Q: How are VSEC's operations aligned with economic cycles?
A: VSEC provides vehicle and supply chain support, often benefiting from steady government contracts. This stability may help buffer economic downturns as government spending typically continues in defense sectors despite economic cycles.
Q: What are the competitive advantages of AIM in its sector?
A: AIM specializes in developing pilot-plant technologies crucial for various industries, including defense. Their niche expertise and R&D investment offer competitive advantages in rapidly evolving markets.
Q: How does KTOS position itself for growth in times of increased geopolitical tension?
A: KTOS focuses on unmanned systems and high-performance defense solutions, sectors that see increased demand during geopolitical tensions. Their investments in autonomous technologies suggest potential adaptability and growth in such climates.
Biotechnology firms are increasingly turning to innovative combination therapies to tackle hard-to-treat cancers, with promising results sparking investor interest. AIM ImmunoTech Inc. AIM is the latest to capture attention, as its stock soars following a promising mid-year update from the DURIPANC Phase 2 study.
Read more